These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
132 related articles for article (PubMed ID: 9299966)
1. ProC Global: the first functional screening assay for the complete protein C pathway. Dati F; Hafner G; Erbes H; Prellwitz W; Kraus M; Niemann F; Noah M; Wagner C Clin Chem; 1997 Sep; 43(9):1719-23. PubMed ID: 9299966 [TBL] [Abstract][Full Text] [Related]
2. Screening for abnormalities of the protein C anticoagulant pathway using the ProC Global assay. Results of a European multicenter evaluation. Toulon P; Halbmeyer WM; Hafner G; Schmitt Y; Randgard B; Odpadlik M; Van Den Eynden C; Wagner C Blood Coagul Fibrinolysis; 2000 Jul; 11(5):447-54. PubMed ID: 10937806 [TBL] [Abstract][Full Text] [Related]
3. Screening for risk factors for thrombosis using a new generation of assays developed to evaluate the functionality of the protein C anticoagulant pathway. Toulon P; Perez P Hematol Oncol Clin North Am; 2000 Apr; 14(2):379-89. PubMed ID: 10806561 [TBL] [Abstract][Full Text] [Related]
4. Modification of the ProC Global assay using dilution of patient plasma in factor V-depleted plasma as a screening assay for factor V Leiden mutation. Quincampoix JC; Legarff M; Rittling C; Andiva S; Toulon P Blood Coagul Fibrinolysis; 2001 Oct; 12(7):569-76. PubMed ID: 11685046 [TBL] [Abstract][Full Text] [Related]
5. The reduced sensitivity of the ProC Global test in protein S deficient subjects reflects a reduction in the associated thrombotic risk. Gemmati D; Serino ML; Tognazzo S; Ongaro A; Moratelli S; Gilli G; Forini E; De Mattei M; Scapoli GL Blood Coagul Fibrinolysis; 2001 Dec; 12(8):691-7. PubMed ID: 11734670 [TBL] [Abstract][Full Text] [Related]
6. [Clinical usefulness of global assays of the anticoagulant pathway of protein C]. Toulon P Ann Biol Clin (Paris); 2001; 59(5):545-50. PubMed ID: 11602384 [TBL] [Abstract][Full Text] [Related]
7. ProC global: a new automated screening assay for the evaluation of total function of the protein C system. Dragoni F; Tormene D; Simioni P; Arcieri P; Avvisati G; Girolami A Clin Appl Thromb Hemost; 2001 Oct; 7(4):351-5. PubMed ID: 11697723 [TBL] [Abstract][Full Text] [Related]
8. "ProC Global": a functional screening test that predicts recurrent venous thromboembolism. Grand'Maison A; Bates SM; Johnston M; McRae S; Ginsberg JS Thromb Haemost; 2005 Mar; 93(3):600-4. PubMed ID: 15735816 [TBL] [Abstract][Full Text] [Related]
9. Screening for thrombophilia: a laboratory perspective. Jennings I; Cooper P Br J Biomed Sci; 2003; 60(1):39-51. PubMed ID: 12680634 [TBL] [Abstract][Full Text] [Related]
10. Sensitivity of the ProC global assay for protein C pathway abnormalities. clinical experience in 899 unselected patients with venous thromboembolism. Toulon P; Adda R; Perez P Thromb Res; 2001 Oct; 104(2):93-103. PubMed ID: 11672753 [TBL] [Abstract][Full Text] [Related]
11. The clinical application of a new specific functional assay to detect the factor V(Leiden) mutation associated with activated protein C resistance. van Oerle R; van Pampus L; Tans G; Rosing J; Hamulyák K Am J Clin Pathol; 1997 May; 107(5):521-6. PubMed ID: 9128263 [TBL] [Abstract][Full Text] [Related]
12. ProC Global assay in the evaluation of women with history of severe preeclampsia or HELLP syndrome. Heilmann L; von Tempelhoff GF; Pollow K Clin Appl Thromb Hemost; 2002 Oct; 8(4):319-24. PubMed ID: 12518722 [TBL] [Abstract][Full Text] [Related]
13. An evaluation of screening tests for defects in the protein C pathway: commercial kits lack sensitivity and specificity. Gardiner C; Cooper PC; Makris M; Mackie IJ; Malia RG; Machin SJ Blood Coagul Fibrinolysis; 2002 Mar; 13(2):155-63. PubMed ID: 11914658 [TBL] [Abstract][Full Text] [Related]
14. A comparison between two activated protein C resistance methods as routine diagnostic tests for factor V Leiden mutation. Aboud MR; Ma DD Br J Haematol; 1997 Jun; 97(4):798-803. PubMed ID: 9217178 [TBL] [Abstract][Full Text] [Related]
15. [Diagnosis of thrombophilia based on coagulation and genetic studies]. Bałszan-Kowalska I Ann Acad Med Stetin; 2002; 48():179-93. PubMed ID: 14601477 [TBL] [Abstract][Full Text] [Related]
16. A modified functional global test to measure protein C, protein S activities and the activated protein C-resistance phenotype. Gemmati D; Serino ML; Scapoli GL Thromb Res; 1998 Nov; 92(3):141-8. PubMed ID: 9806366 [TBL] [Abstract][Full Text] [Related]
17. A more discriminating test for APC resistance and a possible screening test to include protein C and protein S. Denson KW; Haddon ME; Reed SV; Davidson S; Littlewood TJ Thromb Res; 1996 Jan; 81(1):151-6. PubMed ID: 8747530 [No Abstract] [Full Text] [Related]
18. Evaluation of a new screening assay ProC Global for identification of defects in the protein C/protein S anticoagulant pathway. Ruzicka K; Kapiotis S; Quehenberger P; Handler S; Pabinger-Fasching I; Mannhalter C; Jilma B; Speiser W Thromb Res; 1997 Sep; 87(6):501-10. PubMed ID: 9330432 [TBL] [Abstract][Full Text] [Related]
19. Prevalence of hereditary thrombophilia in patients with thrombosis in different venous systems. Bombeli T; Basic A; Fehr J Am J Hematol; 2002 Jun; 70(2):126-32. PubMed ID: 12111785 [TBL] [Abstract][Full Text] [Related]
20. An abnormal ProC Global test result is associated with an increased risk of venous thromboembolism independent of test sensitivity for protein C pathway abnormalities. Toulon P; Perez P; Rapp J; Adda R Thromb Haemost; 2007 Jul; 98(1):228-33. PubMed ID: 17598017 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]